Titan Biotech
BSE: TITANBIO · Specialty Chemicals
Snapshot
Unlock Titan Biotech's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Titan Biotech Ltd. is a manufacturer and exporter of biological products catering to diverse sectors including pharmaceuticals, nutraceuticals, food and beverages, and biotechnology. The company specialises in microbiology culture media and plant tissue culture media, serving both domestic and international markets.
Business Model
The company generates revenue through the production and sale of specialised biological ingredients and culture media used in industrial fermentation and laboratory research. It operates as a holding company with a focus on high-growth life sciences and agricultural supply chains.
- Founded:1992
Growth Outlook
Growth is driven by the increasing demand for high-quality culture media in the pharmaceutical and biotechnology sectors. Expansion into global markets for animal feed and agricultural biotechnology remains a key strategic focus.
Key Risks
- Regulatory Compliance. Changes in international quality standards for pharmaceutical and food-grade biological products could impact export capabilities.
- Raw Material Volatility. Fluctuations in the cost of organic raw materials used in fermentation processes may affect profit margins.
- Competitive Pressure. The specialty chemicals and biological products market is highly fragmented, leading to intense pricing competition from both domestic and global players.
- Currency Risk. As an exporter, the company is exposed to foreign exchange rate fluctuations that can impact the profitability of international contracts.
Price
Start your research today
Unlock AI insights, financials, peers and live data on Titan Biotech and 5,000+ companies — free.
Key Metrics
REVENUE
₹206 Cr
TTM · consolidated
NET PROFIT
₹30 Cr
TTM · consolidated
EPS
₹29.65
TTM · consolidated
RETURN ON EQUITY
18.6%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
23.7%
TTM · consolidated
P/E
14.1x
Q4 FY26 · consolidated
EV/EBITDA
39.4x
Q4 FY26 · consolidated
EBITDA MARGIN
21.3%
TTM · consolidated
NET PROFIT MARGIN
13.8%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.0x
Q4 FY26 · consolidated
Peers · Specialty Chemicals
| Company | Mkt Cap (Cr) | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Titan BiotechTITANBIO | 1,665 | 14.12 | 39.35 | 34.5% | 21.3% | 18.6% | 23.7% | -8.0% |
Bhansali Engg.BEPL | 2,137 | 15.15 | 9.18 | -8.7% | 20.0% | 17.6% | 23.7% | -3.8% |
S H Kelkar & Co.SHK | 1,806 | 25.83 | 10.24 | 11.5% | 10.6% | 5.3% | 10.5% | -46.6% |
Yasho IndustriesYASHO | 1,799 | 125.17 | 23.30 | 53.9% | 17.3% | 6.8% | 14.2% | +50.2% |
Godavari Bioref.GODAVARIB | 1,566 | 11.17 | 7.53 | — | 12.3% | 15.2% | 19.3% | -14.6% |
Vidhi SpecialtyVIDHIING | 1,412 | 30.42 | 19.20 | -0.6% | 21.0% | 15.9% | 22.2% | -25.9% |
As of Q4 FY26
Financials
Titan Biotech
BSE: TITANBIO · Specialty Chemicals
Snapshot
Unlock Titan Biotech's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Titan Biotech Ltd. is a manufacturer and exporter of biological products catering to diverse sectors including pharmaceuticals, nutraceuticals, food and beverages, and biotechnology. The company specialises in microbiology culture media and plant tissue culture media, serving both domestic and international markets.
Business Model
The company generates revenue through the production and sale of specialised biological ingredients and culture media used in industrial fermentation and laboratory research. It operates as a holding company with a focus on high-growth life sciences and agricultural supply chains.
- Founded:1992
Growth Outlook
Growth is driven by the increasing demand for high-quality culture media in the pharmaceutical and biotechnology sectors. Expansion into global markets for animal feed and agricultural biotechnology remains a key strategic focus.
Key Risks
- Regulatory Compliance. Changes in international quality standards for pharmaceutical and food-grade biological products could impact export capabilities.
- Raw Material Volatility. Fluctuations in the cost of organic raw materials used in fermentation processes may affect profit margins.
- Competitive Pressure. The specialty chemicals and biological products market is highly fragmented, leading to intense pricing competition from both domestic and global players.
- Currency Risk. As an exporter, the company is exposed to foreign exchange rate fluctuations that can impact the profitability of international contracts.
Price
Loading…
Start your research today
Unlock AI insights, financials, peers and live data on Titan Biotech and 5,000+ companies — free.
Key Metrics
REVENUE
₹206 Cr
TTM · consolidated
NET PROFIT
₹30 Cr
TTM · consolidated
EPS
₹29.65
TTM · consolidated
RETURN ON EQUITY
18.6%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
23.7%
TTM · consolidated
P/E
14.1x
Q4 FY26 · consolidated
EV/EBITDA
39.4x
Q4 FY26 · consolidated
EBITDA MARGIN
21.3%
TTM · consolidated
NET PROFIT MARGIN
13.8%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.0x
Q4 FY26 · consolidated
Peers · Specialty Chemicals
As of Q4 FY26